Uneingeschränkter Zugang

Effects of early dexamethasone treatment on several markers of inflammation and fibrosis in an animal model of lung silicosis in rats – A pilot study

Adamcakova Jana
Adamcakova Jana
, 
Balentova Sona
Balentova Sona
, 
Hanusrichterova Juliana
Hanusrichterova Juliana
, 
Barosova Romana
Barosova Romana
, 
Mikolka Pavol
Mikolka Pavol
, 
Prso Kristian
Prso Kristian
, 
Mokry Juraj
Mokry Juraj
, 
Kalenska Dagmar
Kalenska Dagmar
, 
Kunertova Lenka
Kunertova Lenka
 und 
Mokra Daniela
Mokra Daniela
   | 22. Dez. 2022
Acta Medica Martiniana's Cover Image
Über diesen Artikel
Vorheriger Artikel
Nächster Artikel
Zitieren
Online veröffentlicht: 22. Dez. 2022
Seitenbereich: 102 - 114
Eingereicht: 18. Okt. 2022
Akzeptiert: 13. Nov. 2022
DOI: https://doi.org/10.2478/acm-2022-0012
© 2022 Mokra D. et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Fig 1

Differential count of leukocytes in the blood (%) in the control groups with saline instead of silica (Sal), in the silica-injected and non-treated animals (Sil), and in the silica-injected and dexamethasone-treated animals (Dex) after 14 or 28 days of the treatment delivery. Abbreviations: Ly: lymphocytes, Neu: neutrophils, Mo: monocytes, Eo: eosinophils. Statistical differences among the groups: a p<0.05 for Sil14 vs Sal14; b p<0.05 for Sil28 vs Sil14; c p<0.05 for Dex14 vs Sil14; d p<0.05 for Dex28 vs Sil28.
Differential count of leukocytes in the blood (%) in the control groups with saline instead of silica (Sal), in the silica-injected and non-treated animals (Sil), and in the silica-injected and dexamethasone-treated animals (Dex) after 14 or 28 days of the treatment delivery. Abbreviations: Ly: lymphocytes, Neu: neutrophils, Mo: monocytes, Eo: eosinophils. Statistical differences among the groups: a p<0.05 for Sil14 vs Sal14; b p<0.05 for Sil28 vs Sil14; c p<0.05 for Dex14 vs Sil14; d p<0.05 for Dex28 vs Sil28.

Fig 2

Differential count of leukocytes in the BAL fluid (%) in the control groups with saline instead of silica (Sal), in the silica-injected and non-treated animals (Sil), and in the silica-injected and dexamethasone-treated animals (Dex) after 14 or 28 days of the the treatment delivery. Abbreviations: Ma: macrophages, Neu: neutrophils, Eo: eosinophils, Ly: lymphocytes. Statistical differences among the groups: a p<0.05 and b p<0.001 for Sil14 vs Sal14; d p<0.05 and e p<0.001 for Sil28 vs Sal28; f p<0.05 for Sil28 vs Sil14; g p<0.05 and h p<0.01 for Dex28 vs Sil28.
Differential count of leukocytes in the BAL fluid (%) in the control groups with saline instead of silica (Sal), in the silica-injected and non-treated animals (Sil), and in the silica-injected and dexamethasone-treated animals (Dex) after 14 or 28 days of the the treatment delivery. Abbreviations: Ma: macrophages, Neu: neutrophils, Eo: eosinophils, Ly: lymphocytes. Statistical differences among the groups: a p<0.05 and b p<0.001 for Sil14 vs Sal14; d p<0.05 and e p<0.001 for Sil28 vs Sal28; f p<0.05 for Sil28 vs Sil14; g p<0.05 and h p<0.01 for Dex28 vs Sil28.

Fig 3

Thickness of the wall of bronchioles and pulmonary vessels (in μm) – staining for presence of collagen by Sirius red in the control groups with saline instead of silica (Sal), in the silica-injected and non-treated animals (Sil), and in the silica-injected and dexamethasone-treated animals (Dex) after 14 or 28 days of the treatment delivery. Statistical differences among the groups: a p<0.05 for Sal28 vs Sal14, b p<0.001 for Sil14 vs Sal14, c p<0.01 for Sil14 vs Sal14, d p<0.001 for Sil28 vs Sal28, e p<0.01 for Sil28 vs Sal28, f p<0.01 for Dex14 vs Sil14, g p<0.001 for Dex28 vs Sil28.
Thickness of the wall of bronchioles and pulmonary vessels (in μm) – staining for presence of collagen by Sirius red in the control groups with saline instead of silica (Sal), in the silica-injected and non-treated animals (Sil), and in the silica-injected and dexamethasone-treated animals (Dex) after 14 or 28 days of the treatment delivery. Statistical differences among the groups: a p<0.05 for Sal28 vs Sal14, b p<0.001 for Sil14 vs Sal14, c p<0.01 for Sil14 vs Sal14, d p<0.001 for Sil28 vs Sal28, e p<0.01 for Sil28 vs Sal28, f p<0.01 for Dex14 vs Sil14, g p<0.001 for Dex28 vs Sil28.

Fig 4

Thickness of the wall of bronchioles and pulmonary vessels (in μm) – staining for presence of smooth muscle actin (SMA) by antibody against SMA in the control groups with saline instead of silica (Sal), in the silica-injected and non-treated animals (Sil), and in the silica-injected and dexamethasone-treated animals (Dex) after 14 or 28 days of the treatment delivery. Statistical differences among the groups: a p<0.05 for Sil14 vs Sal14, b p<0.001 for Sil28 vs Sal28, c p<0.01 for Sil28 vs Sal28, d p<0.01 for Dex14 vs Sil14, e p<0.001 for Dex28 vs Sil28.
Thickness of the wall of bronchioles and pulmonary vessels (in μm) – staining for presence of smooth muscle actin (SMA) by antibody against SMA in the control groups with saline instead of silica (Sal), in the silica-injected and non-treated animals (Sil), and in the silica-injected and dexamethasone-treated animals (Dex) after 14 or 28 days of the treatment delivery. Statistical differences among the groups: a p<0.05 for Sil14 vs Sal14, b p<0.001 for Sil28 vs Sal28, c p<0.01 for Sil28 vs Sal28, d p<0.01 for Dex14 vs Sil14, e p<0.001 for Dex28 vs Sil28.

Absolute counts of leukocytes in the blood and in the BAL fluid in the control groups with saline instead of silica (Sal), in the silica-injected and non-treated animals (Sil), and in the silica-injected and dexamethasone-treated animals (Dex) after 14 or 28 days of the treatment delivery.

14 days 28 days
Leukocytes in the blood (x 109/L)
Sal14 Sil14 Dex14 Sal28 Sil28 Dex28
Ly 2.95±1.07 4.33±0.84 a 1.99±0.87 g 3.21±0.83 4.18±1.23 1.42±0.53 j
Neu 0.63±0.19 0.97±0.40 1.14±0.40 0.61±0.22 0.67±0.22 1.49±0.79 h
Mo 0.04±0.02 0.03±0.01 0.04±0.02 0.05±0.03 0.05±0.02 0.03±0.01
Eo 0.03±0.03 0.04±0.04 0.05±0.05 0.03±0.04 0.06±0.04 0.04±0.02
Leukocytes in the BAL fluid (x 103/mL)
Sal14 Sil14 Dex14 Sal28 Sil28 Dex28
Ma 97.7±41.5 95.4±37.7 146±38.8 f 107±45.9 102±43.8 84.3±42.4
Neu 2.29±1.66 14.3±3.83 c 35.1±49.9 3.51±1.35 26.8±24.1 d 8.68±5.23
Eo 0.25±0.32 0.81±0.23 b 1.47±1.57 0.23±0.23 2.39±2.17 d 0.62±0.35 h
Ly 0.99±0.64 2.35±1.70 4.06±2.10 0.71±0.27 4.92±2.89 e 1.40±0.87 i
eISSN:
1338-4139
Sprache:
Englisch
Zeitrahmen der Veröffentlichung:
3 Hefte pro Jahr
Fachgebiete der Zeitschrift:
Medizin, Klinische Medizin, Allgemeinmedizin, Innere Medizin, Kardiologie
Zeitschrift RSS Feed